Business Standard

USFDA's drug approvals for Indian firms halved in H1CY21: Report

ANDAs granted have halved in H12021, compared to pre-pandemic levels

usfda, pharma
Premium

Sohini Das Mumbai
The pace of approvals for abbreviated new drug applications (ANDAs) by the US drug regulator has halved, compared to pre-Covid levels, revealed the latest data from India Ratings & Research (Ind-Ra).

Compared to 670 global ANDA approvals given by the US Food and Drug Administration (USFDA) in the first half (H1) of calendar year 2019, the number of approvals has halved to 328 in H12021 (calendar).

Within this, the ANDA approvals secured by Indian pharmaceutical (pharma) firms have fallen from 267 in H12019 (calendar) to 137 in H12021 (calendar) - a 49-per cent drop.

India’s share in the global ANDA

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in